Healios K.K (TYO:4593) has completed regulatory consultations with Japan's Pharmaceuticals and Medical Devices Agency for its conditional approval application for HLCM051 (invimestrocel), a treatment for acute respiratory distress syndrome, according to a Wednesday filing on the Tokyo Stock Exchange.
The company will now include Japanese patients in the global Phase 3 revive-ARDS study, set to begin primarily in the US.
The trial aims to confirm efficacy based on ventilator-free days, with a maximum of 550 participants.
Shares of the company gained over 1% in Thursday's morning trade.
Price (JPY): $312.00, Change: $+34, Percent Change: +12.23%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.